DK2344449T3 - Aryl-phenyl-sulfonamido-cycloalkylforbindelser og deres anvendelse - Google Patents

Aryl-phenyl-sulfonamido-cycloalkylforbindelser og deres anvendelse Download PDF

Info

Publication number
DK2344449T3
DK2344449T3 DK09785121.6T DK09785121T DK2344449T3 DK 2344449 T3 DK2344449 T3 DK 2344449T3 DK 09785121 T DK09785121 T DK 09785121T DK 2344449 T3 DK2344449 T3 DK 2344449T3
Authority
DK
Denmark
Prior art keywords
independently
cancer
present
compound
saturated aliphatic
Prior art date
Application number
DK09785121.6T
Other languages
English (en)
Inventor
Iain Robert Greig
Rose Mary Sheridan
Raymond Fisher
Matthew John Tozer
Juha Andrew Clase
Andrew Smith
Andrew Robert Tuffnell
T Hof Robert Jurgen Van
Original Assignee
Pimco 2664 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pimco 2664 Ltd filed Critical Pimco 2664 Ltd
Application granted granted Critical
Publication of DK2344449T3 publication Critical patent/DK2344449T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/52—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Claims (29)

1. Forbindelse udvalgt fra forbindelser med den følgende formel og farmaceutisk acceptable salte, hydrater og solvater deraf:
hvor: -A uafhængigt er:
-Ar uafhængigt er phenyl, pyridinyl eller pyrimidinyl; og p uafhængigt er et helt tal fra 0 til 3; og hvor: q uafhængigt er et helt tal fra 0 til 3; og hvor: -Rsn uafhængigt er -H eller mættet alifatisk Ci_4alkyl; og hvor: -DQ uafhængigt er -D1-Q1 eller -D2=0; -D1- uafhængigt er cyclopentan-di-yl, cyclohexan-di-yl, cycloheptan-di-yl, bicyclo[3.1.1 ]heptan-di-yl eller bicyclo[3.2.1]octan-di-yl og eventuelt er substitueret med en eller flere grupper -R°; -D2= uafhængigt er cyclopentan-yl-yliden, cyclohexan-yl-yliden, cycloheptan- yl-yliden, bicyclo[3.1,1]heptan-yl-yliden eller bicyclo[3.2.1]octan-yl-ylid og eventuelt er substitueret med en eller flere grupper -R°; hvert -Rd uafhængigt er udvalgt fra -F, -Cl, -Br, -I, -RDD, -CF3, -OH, -ORDD, -NH2, -NHRdd og -NRdd2; og hvert -Rdd uafhængigt er mættet alifatisk Ci-4alkyl; og hvor -Q1 uafhængigt er udvalgt fra:
hvor: hvert -R1N uafhængigt er -H, -RCN, eller -RCF; hvert -R2N uafhængigt er -H, -RCN eller -RCF; hvert -Rcn uafhængigt er mættet alifatisk Ci-4alkyl; og hvert -Rcf, hvis til stede, uafhængigt er mættet alifatisk Ci_4fluoralkyl; eller: -NR1NR2N uafhængigt er azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, azepino eller diazepino, hver især eventuelt substitueret med en eller flere grupper uafhængigt udvalgt fra mættet alifatisk Ci_4alkyl; -R1A uafhængigt er -H, -Rc eller -RF; og -R2A uafhængigt er -H, -Rc eller -RF; eller -R1A og -R2A sammen danner en mættet alifatisk C2-4alkylengruppe; -R1B uafhængigt er -H, -Rc eller -RF; og -R2B uafhængigt er -H, -Rc eller -RF; eller -R1B og -R2B sammen danner en mættet alifatisk C2-4alkylengruppe; eller -R1B og -R2B sammen danner =0; -R3A uafhængigt er -H, -Rc eller -RF; og -R4A uafhængigt er -H, -Rc eller -RF; eller -R3A og -R4A sammen danner en mættet alifatisk C2-4alkylengruppe; -R5A uafhængigt er -H, -Rc, -RF eller -RJ; og -R6A uafhængigt er -H, -Rc eller -RF; eller -R5A og -R6A sammen danner en mættet alifatisk C2-4alkylengruppe; -R3B uafhængigt er -H, -Rc eller -RF; og -R4B uafhængigt er -H, -Rc eller -RF; eller -R3B og -R4B sammen danner en mættet alifatisk C2-4alkylengruppe; -R5B uafhængigt er -H, -Rc, -RF, -OH eller -OR0; og -R6B uafhængigt er -H, -Rc eller -RF; eller -R5B og -R6B sammen danner en mættet alifatisk C2-4alkylengruppe; hvert -Rc uafhængigt er mættet alifatisk Ci-4alkyl; hvert -Rf uafhængigt er mættet alifatisk Ci_4fluoralkyl; -R° uafhængigt er mættet alifatisk Ci-4alkyl; -RJ uafhængigt er -NH2, -NHRjn1, -NRjn12 eller -NRJN2RJN3; hvert -RJN1 uafhængigt er mættet alifatisk Ci-4alkyl; og -NRJN2Rjns uafhængigt er azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, azepino eller diazepino, hver især eventuelt substitueret med en eller flere grupper uafhængigt udvalgt fra mættet alifatisk Ci-4alkyl; og hvor hvert -Rx uafhængigt er: -F, -Cl, -Br, -I, -Rxx, -OH, -ORxx, -SH, -SRXX, -CF3, -OCF3, -SCF3i -NH2i -NHRxx, -NRxx2, -NR^R22, -C(=0)Rxx, -0C(=0)Rxx, -C(=0)0H, -C(=0)0Rxx, -C(=0)NH2, -C(=0)NHRxx, -C(=0)NRxx2, -C(=0)NRyyR22, -0C(=0)NH2i -0C(=0)NHRxx, -0C(=0)NRxx2, -0C(=0)NRyyR22, -NHC(=0)Rxx, -NRxxC(=0)Rxx, -NHC(=0)0Rxx, -NRxxC(=0)0Rxx, -NHC(=0)NH2, -NHC(=0)NHRxx, -NHC(=0)NRxx2, -NHC(=0)NRyyR22, -NRxxC(=0)NH2, -NRxxC(=0)NHRxx, -NRxxC(=0)NRxx2, -NRxxC(=0)NRyyR22, -CN, -N02, -S(=0)2NH2i -S(=0)2NHRxx, -S(=0)2NRxx2, -S(=0)2NRyyR22, -S(=0)Rxx, -S(=0)2Rxx, -0S(=0)2Rxx, -S(=0)20H eller -S(=0)20Rxx; hvor: hvert -Rxx uafhængigt er mættet alifatisk Ci-6alkyl, phenyl eller benzyl, hvor phenylen og benzylen eventuelt er substitueret med en eller flere grupper udvalgt fra: -F, -Cl, -Br, -I, -CF3, -OCF3, -Rxxx, -OH, -ORxxx eller -SRXXX, hvor hvert -Rxxx uafhængigt er mættet alifatisk Ci-4alkyl; og hvert -NR^R22 uafhængigt er azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, azepino eller diazepino, hver især eventuelt substitueret med en eller flere grupper uafhængigt udvalgt fra mættet alifatisk Ci-4alkyl.
2. Forbindelse ifølge krav 1, hvor: hvert -Rx uafhængigt er -F, -Cl, -Br, -I, -Rxx, -OH, -ORxx, -SRXX, -CF3, -OCF3, -CN eller -N02; og hvert -Rxx uafhængigt er mættet alifatisk C^alkyl.
3. Forbindelse ifølge krav 1 eller 2, hvor -A uafhængigt er:
hvor: =W- er -CH= og -Y= er -CH=; -RX2 uafhængigt er -H eller -RX2S; -RX4 uafhængigt er -H eller -RX4S; -RX2S uafhængigt er -Rx; og -RX4S uafhængigt er -Rx.
4. Forbindelse ifølge krav 1 eller 2, hvor -A uafhængigt er:
hvor: =W- er -CH= og -Y= er -N=; -RX2 uafhængigt er -Fl eller -RX2S; -RX4 uafhængigt er -Fl eller -RX4S; -RX2S uafhængigt er -Rx; og -RX4S uafhængigt er -Rx.
5. Forbindelse ifølge krav 3 eller 4, hvor: -RX2 uafhængigt er -RX2S; og -RX4 uafhængigt er -RX4S.
6. Forbindelse ifølge et af kravene 3 til 5, hvor: -RX2S uafhængigt er -F, -Cl eller -CF3; og -RX4S uafhængigt er -F, -Cl eller -CF3.
7. Forbindelse ifølge et af kravene 3 til 5, hvor: -RX2S uafhængigt er -F; og -RX4S uafhængigt er -F.
8. Forbindelse ifølge et af kravene 3 til 5, hvor: -RX2S uafhængigt er -Cl; og -RX4S uafhængigt er -Cl.
9. Forbindelse ifølge et af kravene 1 til 8, hvor den ledende phenylengruppe:
er:
hvor: -RXC1 uafhængigt er -H eller -Rxcc; -RXC2 uafhængigt er -H; hvert -Rxcc uafhængigt er -F, -Cl eller .rxccc; og hvert -Rxccc uafhængigt er -Me eller -Et.
10. Forbindelse ifølge krav 9, hvor: '-RXC1 uafhængigt er -H; og -RXC2 uafhængigt er -H.
11. Forbindelse ifølge et af kravene 1 til 10, hvor-RSN uafhængigt er -H.
12. Forbindelse ifølge krav 1, hvor-DQ uafhængigt er-D1-Q1.
13. Forbindelse ifølge et af kravene 1 til 12, hvor -D1- uafhængigt er cyclohe-xan-1,4-di-yl.
14. Forbindelse ifølge et af kravene 1 til 12, hvor -D1- uafhængigt er 4-methyl-cyclohexan-1,4-di-yl.
15. Forbindelse ifølge et af kravene 1 til 14, hvor -Q1 uafhængigt er:
16. Forbindelse ifølge et af kravene 1 til 14, hvor -Q1 uafhængigt er:
hvor: -R1A uafhængigt er -Fl eller -Rc; -R2A uafhængigt er -Fl eller -Rc; og hvert -Rc uafhængigt er -Me eller -Et.
17. Forbindelse ifølge et af kravene 1 til 14, hvor -Q1 uafhængigt er:
hvor: enten: -R1N uafhængigt er -Fl eller -RCN; -R2N uafhængigt er -Fl eller -RCN; og hvert -Rcn uafhængigt er -Me eller -Et; eller: -NR1NR2N uafhængigt er pyrrolidino, piperidino, piperazino eller morpholino, hver især eventuelt substitueret med en eller flere grupper uafhængigt udvalgt fra mættet alifatisk Ci-4alkyl.
18. Forbindelse ifølge et af kravene 1 til 14, hvor -Q1 uafhængigt er:
hvor: -R1B uafhængigt er -H eller -Rc; -R2B uafhængigt er -H eller -Rc; og hvert -Rc uafhængigt er -Me eller -Et; og hvor: enten: -R1N uafhængigt er -H eller -RCN; -R2N uafhængigt er -H eller -RCN; og hvert -Rcn uafhængigt er -Me eller -Et; eller: -NR1NR2N uafhængigt er pyrrolidino, piperidino, piperazino eller morpholino, hver især eventuelt substitueret med en eller flere grupper uafhængigt udvalgt fra mættet alifatisk Ci_4alkyl.
19. Forbindelse ifølge krav 1, hvor: -A uafhængigt er:
hvor: =W- er -CH= og -Y= er -CH=; -RX2 uafhængigt er -RX2S; -RX4 uafhængigt er -RX4S; -RX2S uafhængigt er -F; og -RX4S uafhængigt er -F; den ledende phenylengruppe:
er:
hvor: '-RXC1 uafhængigt er -H; og -RXC2 uafhængigt er -H; -Rsn uafhængigt er -H; -DQ uafhængigt er -D1-Q1; -D1- uafhængigt er 4-methyl-cyclohexan-1,4-di-yl; og -Q1 uafhængigt er:
20. Forbindelse ifølge krav 1, udvalgt fra de følgende forbindelser og farmaceutiske acceptable salte, hydrater og solvater deraf:
(ABD599), (ABD655), (ABD665), (ABD679), (ABD682), (ABD683), (ABD684), (ABD698),
(ABD699), (ABD702), (ABD703), (ABD704), (ABD705), (ABD706), (ABD710), (ABD712), (ABD714),
(ABD716), (ABD730), (ABD732), (ABD735), (ABD742), (ABD756), (ABD769), (ABD770),
(ABD771), (ABD772), (ABD773), (ABD774), (ABD775), (ABD776), (ABD777), (ABD781), (ABD786),
(ABD787), (ABD794), (AB D795), (ABD796), (ABD797), (ABD798), (ABD799), i (ABD800), (ABD812),
(ABD813), (ABD814), I (ABD815), (ABD816), (ABD817), (ABD818), (ABD819), (ABD820), (ABD821), (ABD822),
(ABD823), (ABD824), (ABD824a), (ABD825), (ABD826), (ABD826a), (ABD827), (ABD828),
(ABD836), (ABD837), (ABD839), (ABD840), (ABD841), (ABD842), (ABD843), (ABD844), (ABD845),
(ABD846), (ABD847), (ABD848), (ABD849), (ABD861), (ABD863), (ABD864), (ABD865), (ABD868), (ABD899),
(ABD900), (ABD901), (ABD902) (ABD903).
21. Forbindelse ifølge krav 1, som er den følgende forbindelse eller et farmaceutisk acceptabelt salt, hydrat eller solvat deraf:
(ABD735).
22. Forbindelse ifølge krav 1, som er den følgende forbindelse eller et farmaceutisk acceptabeltsalt, hydrat eller solvat deraf:
(ABD836).
23. Forbindelse ifølge krav 1, som er den følgende forbindelse eller et farmaceutisk acceptabelt salt, hydrat eller solvat deraf:
(ABD899).
24. Forbindelse ifølge krav 1, som er den følgende forbindelse eller et farmaceutisk acceptabelt salt, hydrat eller solvat deraf:
(ABD90Q).
25. Farmaceutisk sammensætning omfattende en forbindelse ifølge et af kravene 1 til 24 og en farmaceutisk acceptabel bærer, fortyndingsmiddel eller excipiens.
26. Fremgangsmåde til fremstilling af en farmaceutisk sammensætning omfattende sammenblanding afen forbindelse ifølge et af kravene 1 til 24 og en farmaceutisk acceptabel bærer, fortyndingsmiddel eller excipiens.
27. Forbindelse ifølge et af kravene 1 til 24 til anvendelse i en fremgangsmåde til behandling af menneske- eller dyrekroppen ved terapi.
28. Forbindelse ifølge et af kravene 1 til 24 til anvendelse i en fremgangsmåde til behandling af: en inflammatorisk forstyrrelse eller en autoimmun forstyrrelse; en forstyrrelse associeret med inflammation og/eller aktivering af immunsystemet; en forstyrrelse medieret af overdreven og/eller uhensigtsmæssig og/eller forlænget aktivering af immunsystemet; inflammation; en forstyrrelse associeret med inflammation eller aktivering af immunsystemet; reumatoid artritis; psoriasis; psoriasis artritis; kronisk obstruktiv lungesygdom (COPD); aterosklerose; spondylitis ankylopoetica; inflammatorisk tarmsygdom; en immunreaktion, som resulterer i organ- eller transplantatafstødning efter transplantation; en tumor, som overeksprimerer TNFa, IL-1, RANKL eller NFkB, eller hvor inhibering af TNFa, IL-1, RANKL eller NFkB fremmer eller forbedrer virkningen af cytotoksiske tumordræbende midler; en hæmatologisk malignitet; en hæmatologisk malignitet associeret med aktivering af NFkB, med aberrerende NFkB signalering eller med inflammation; myelomatose, leukæmi eller lymfom; myelomatose, leukæmi eller lymfom associeret med aktivering af NFkB, med aberrerende NFkB signalering eller med inflammation; en fast tumorkræft; en fast tumorkræft associeret med aktivering af NFkB, med aberrerende NFkB signalering eller med inflammation; blærekræft, brystkræft (hos kvinder og/eller mænd), kolonkræft, nyrekræft, lungekræft, bugspytkirtelkræft, prostatakræft, hjernekræft, hudkræft, skjoldbruskkirtel kræft eller melanom; blærekræft, brystkræft (hos kvinder og/eller mænd), kolonkræft, nyrekræft, lungekræft, bugspytkirtelkræft, prostatakræft, hjernekræft, hudkræft, skjold-bruskkirtelkræft eller melanom associeret med aktivering af NFkB, med aberrerende NFkB signalering eller med inflammation; T-celle-lymfoblastlymfom, kappecellelymfom eller akut lymfoblastleukæmi; en hæmatologisk malignitet associeret med inaktivering eller svækkelse af kaspase-induktion eller med aberrerende kaspase-signalering; T-celle-lymfoblastlymfom, kappecellelymfom eller akut lymfoblastleukæmi associeret med inaktivering eller svækkelse af kaspase-induktion eller med aberrerende kaspase-signalering; nyrecellekarcinom, brystkræft (hos kvinder og/eller mænd), mavekræft, prostatakræft, kolonkræft eller basalcelleameloblastom; en fast tumorkræft associeret med inaktivering eller svækkelse af kaspase-induktion eller med aberrerende kaspase-signalering; nyrecellekarcinom, brystkræft (hos kvinder og/eller mænd), mavekræft, pro-statakræft, kolonkræft eller basalcelleameloblastom associeret med inaktivering eller svækkelse af kaspase-induktion eller med aberrerende kaspase-signalering; knogletab; ledødelæggelse; knogletab associeret med reumatoid artritis, osteoporose, kræft-associeret knoglesygdom eller Pagets knoglesygdom; reumatoid artritis, osteoporose, kræft-associeret knoglesygdom eller Pagets knoglesygdom; knogleneoplasi; eller aseptisk løsning af proteseimplantater.
29. Anvendelse af en forbindelse ifølge et af kravene 1 til 24 ved fremstilling af et medikament til behandling af: en inflammatorisk forstyrrelse eller en autoimmun forstyrrelse; en forstyrrelse associeret med inflammation og/eller aktivering af immunsystemet; en forstyrrelse medieret af overdreven og/eller uhensigtsmæssig og/eller forlænget aktivering af immunsystemet; inflammation; en forstyrrelse associeret med inflammation eller aktivering af immunsystemet; reumatoid artritis; psoriasis; psoriasis artritis; kronisk obstruktiv lungesygdom (COPD); aterosklerose; spondylitis ankylopoetica; inflammatorisk tarmsygdom; en immunreaktion, som resulterer i organ- eller transplantatafstødning efter transplantation; en tumor, som overeksprimerer TNFa, IL-1, RANKL eller NFkB, eller hvor inhibering af TNFa, IL-1, RANKL eller NFkB fremmer eller forbedrer virkningen af cytotoksiske tumordræbende midler; en hæmatologisk malignitet; en hæmatologisk malignitet associeret med aktivering af NFkB, med aberrerende NFkB signalering eller med inflammation; myelomatose, leukæmi eller lymfom; myelomatose, leukæmi eller lymfom associeret med aktivering af NFkB, med aberrerende NFkB signalering eller med inflammation; en fast tumorkræft; en fast tumorkræft associeret med aktivering af NFkB, med aberrerende NFkB signalering eller med inflammation; blærekræft, brystkræft (hos kvinder og/eller mænd), kolonkræft, nyrekræft, lungekræft, bugspytkirtelkræft, prostatakræft, hjernekræft, hudkræft, skjoldbruskkirtel kræft eller melanom; blærekræft, brystkræft (hos kvinder og/eller mænd), kolonkræft, nyrekræft, lungekræft, bugspytkirtelkræft, prostatakræft, hjernekræft, hudkræft, skjold-bruskkirtelkræft eller melanom associeret med aktivering af NFkB, med aberrerende NFkB signalering eller med inflammation; T-celle-lymfoblastlymfom, kappecellelymfom eller akut lymfoblastleukæmi; en hæmatologisk malignitet associeret med inaktivering eller svækkelse af kaspase-induktion eller med aberrerende kaspase-signalering; T-celle-lymfoblastlymfom, kappecellelymfom eller akut lymfoblastleukæmi associeret med inaktivering eller svækkelse af kaspase-induktion eller med aberrerende kaspase-signalering; nyrecellekarcinom, brystkræft (hos kvinder og/eller mænd), mavekræft, prostatakræft, kolonkræft eller basalcelleameloblastom; en fast tumorkræft associeret med inaktivering eller svækkelse af kaspase-induktion eller med aberrerende kaspase-signalering; nyrecellekarcinom, brystkræft (hos kvinder og/eller mænd), mavekræft, prostatakræft, kolonkræft eller basalcelleameloblastom associeret med inaktivering eller svækkelse af kaspase-induktion eller med aberrerende kaspase-signalering; knogletab; ledødelæggelse; knogletab associeret med reumatoid artritis, osteoporose, kræft-associeret knoglesygdom eller Pagets knoglesygdom; reumatoid artritis, osteoporose, kræft-associeret knoglesygdom eller Pagets knoglesygdom; knogleneoplasi; eller aseptisk løsning af proteseimplantater.
DK09785121.6T 2008-09-19 2009-09-18 Aryl-phenyl-sulfonamido-cycloalkylforbindelser og deres anvendelse DK2344449T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9827108P 2008-09-19 2008-09-19
GBGB0817207.4A GB0817207D0 (en) 2008-09-19 2008-09-19 therapeutic apsac compounds and their use
PCT/GB2009/002221 WO2010032009A1 (en) 2008-09-19 2009-09-18 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use

Publications (1)

Publication Number Publication Date
DK2344449T3 true DK2344449T3 (da) 2015-08-17

Family

ID=39951895

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09785121.6T DK2344449T3 (da) 2008-09-19 2009-09-18 Aryl-phenyl-sulfonamido-cycloalkylforbindelser og deres anvendelse

Country Status (14)

Country Link
US (5) US8435968B2 (da)
EP (1) EP2344449B1 (da)
JP (1) JP5771524B2 (da)
CA (1) CA2736971C (da)
CY (1) CY1116650T1 (da)
DK (1) DK2344449T3 (da)
ES (1) ES2544511T3 (da)
GB (1) GB0817207D0 (da)
HR (1) HRP20150839T1 (da)
PL (1) PL2344449T3 (da)
PT (1) PT2344449E (da)
SI (1) SI2344449T1 (da)
SM (1) SMT201500218B (da)
WO (1) WO2010032009A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0705400D0 (en) * 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US8394858B2 (en) * 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
CA2869143A1 (en) 2012-04-10 2013-10-17 Sumitomo Dainippon Pharma Co., Ltd. Novel 1-substituted indazole derivative
GB201311361D0 (en) * 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
HRP20211877T1 (hr) * 2014-12-17 2022-03-04 Pimco 2664 Limited Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
AR114631A1 (es) 2018-02-16 2020-09-30 Gilead Sciences Inc Métodos e intermedios para preparar compuestos de piridina
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
GB201813312D0 (en) * 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
GB201905520D0 (en) * 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB597810A (en) 1943-04-12 1948-02-04 Gen Printing Ink Corp Improvements in or relating to derivatives of diphenyl
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
US4119784A (en) * 1977-07-01 1978-10-10 American Cyanamid Company Anionic substituted sulfonamido biphenyls
DE3000519A1 (de) 1979-02-01 1980-08-14 Byk Gulden Lomberg Chem Fab Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel
DE3535167A1 (de) * 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
HUP9900964A3 (en) 1995-10-30 2001-02-28 Smithkline Beecham Corp Protease inhibitors and pharmaceutical compositions containing these compounds
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
EP0888344A1 (en) 1996-03-15 1999-01-07 The Du Pont Merck Pharmaceutical Company Spirocycle integrin inhibitors
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
ATE210637T1 (de) 1996-10-16 2001-12-15 American Cyanamid Co Herstellung und anwendung von ortho-sulfonamido- aryl-hydroxamsäuren als matrix-metalloproteinase- und tace-inhibitoren
DE69736812T2 (de) 1996-11-27 2007-08-09 Bristol-Myers Squibb Pharma Co. Neue integrin rezeptor antagonisten
AU6780398A (en) 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
BR9815469A (pt) 1997-05-08 2001-03-06 Smithkline Beecham Corp Inibidores de protease
PT877019E (pt) 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
ID26219A (id) 1998-01-23 2000-12-07 Aventis Pharma Gmbh Turunan-turunan sulfonamida baru sebagai penghambat-penghambat resorpsi tulang dan adhesi tulang
PL342009A1 (en) 1998-02-04 2001-05-07 Novartis Ag Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
DE19815547C1 (de) 1998-04-07 1999-12-02 Joachim Schmidt Haftmittel für Zahnprothesen
EP0960882A1 (en) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
EP1265886A2 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Carbocyclic side chain containing, n-substituted metalloprotease inhibitors
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
WO2002060867A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
EP1399137A4 (en) * 2001-05-07 2005-12-14 Smithkline Beecham Corp SULPHONAMIDES
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
GB0126157D0 (en) * 2001-10-31 2002-01-02 Univ Aberdeen Therapeutic compounds
TW200305396A (en) 2002-03-27 2003-11-01 Shionogi & Co Cartilage extracellular matrix degradation
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
MXPA05002571A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
DE10251170A1 (de) 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
DE602004010514T2 (de) * 2003-05-07 2008-11-27 The University Court Of The University Of Aberdeen, Aberdeen Ketone und reduzierte ketone als therapeutische mittel zur behandlung von knochenerkrankungen
WO2004106290A1 (ja) 2003-05-14 2004-12-09 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
PE20050948A1 (es) 2003-09-09 2005-12-16 Japan Tobacco Inc Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
GB0324792D0 (en) * 2003-10-23 2003-11-26 Sterix Ltd Compound
BRPI0417687A (pt) 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
GB0405193D0 (en) 2004-03-08 2004-04-21 Medical Res Council Compounds
JP2007530546A (ja) * 2004-03-22 2007-11-01 サザン リサーチ インスティチュート マトリックスメタロプロテイナーゼの非ペプチドインヒビター
WO2005105712A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Sulfonamide derivatives
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
US20090093485A1 (en) 2004-10-29 2009-04-09 Astrazeneca Ab Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
WO2006134467A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
ATE498358T1 (de) 2005-06-29 2011-03-15 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
TW200720261A (en) 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives
SI2395002T1 (sl) 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto
PT1984344E (pt) * 2005-12-29 2012-12-21 Lexicon Pharmaceuticals Inc Derivados de aminoácidos multicíclicos e métodos para a sua utilização
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
WO2008005338A1 (en) * 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
PL2069312T3 (pl) * 2006-07-25 2013-03-29 Cephalon Inc Pochodne pirydazynonu
US7560597B2 (en) * 2007-03-08 2009-07-14 The University Court Of The University Of Aberdeen 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
WO2010025235A1 (en) 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use

Also Published As

Publication number Publication date
JP5771524B2 (ja) 2015-09-02
US9302984B2 (en) 2016-04-05
US9616037B2 (en) 2017-04-11
SI2344449T1 (sl) 2015-09-30
PL2344449T3 (pl) 2015-10-30
EP2344449A1 (en) 2011-07-20
JP2012502964A (ja) 2012-02-02
PT2344449E (pt) 2015-09-16
US20130245018A1 (en) 2013-09-19
CY1116650T1 (el) 2017-03-15
WO2010032009A1 (en) 2010-03-25
HRP20150839T1 (hr) 2015-09-11
SMT201500218B (it) 2015-10-30
GB0817207D0 (en) 2008-10-29
ES2544511T3 (es) 2015-08-31
EP2344449B1 (en) 2015-05-13
US20150266815A1 (en) 2015-09-24
US20110172189A1 (en) 2011-07-14
US9050329B1 (en) 2015-06-09
CA2736971A1 (en) 2010-03-25
US8435968B2 (en) 2013-05-07
US20160206578A1 (en) 2016-07-21
CA2736971C (en) 2017-06-20
US8822507B2 (en) 2014-09-02
US20150141472A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
DK2344449T3 (da) Aryl-phenyl-sulfonamido-cycloalkylforbindelser og deres anvendelse
EP2349990B1 (en) Aryl-phenyl-sulfonamide-phenylene compounds and their use
DK2137141T3 (da) Biphenyl-4-yl-sulfonsyrearylamider og anvendelse deraf som terapeutiske midler
US10233147B2 (en) N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
US20180297955A1 (en) N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use